B cell-targeted therapies in Sjögren's syndrome.
Sjögren's syndrome (SS) or autoimmune epithelitis is characterized by focal lymphocytic infiltrates surrounding the tubular epithelium of exocrine glands and by overactivity of the B-cell population. Although T cells were long considered the main effectors in SS, recent findings indicating a key role for B cells have prompted studies of treatments designed to deplete the B-cell population. Among molecules that can be targeted to achieve B-cell depletion, CD20 and CD22 are surface antigens expressed specifically by B lymphocytes; and the cytokine B-cell-activating factor belonging to the TNF family (BAFF) is a TNF receptor ligand involved in B-cell differentiation, survival, and activation. The aim of this review is to discuss the clinical outcomes of SS patients treated with B-cell depletion.
Tobón
Gabriel J
GJ
EA2216, IFR148, Université de Bretagne Occidentale, Brest, France.
Pers
Jacques Olivier
JO
Youinou
Pierre
P
Saraux
Alain
A
D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000276:immunology; D053264:B-Cell Activating Factor / Q000276:immunology; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D006801:Humans; D007167:Immunotherapy; D008213:Lymphocyte Activation / Q000187:drug effects; D008212:Lymphocyte Depletion; D015202:Protein Engineering; D016032:Randomized Controlled Trials as Topic; D011993:Recombinant Fusion Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000276:immunology; D012859:Sjogren's Syndrome / Q000276:immunology* / Q000628:therapy
D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D053264:B-Cell Activating Factor; D011993:Recombinant Fusion Proteins; D051918:Sialic Acid Binding Ig-like Lectin 2; C505719:TNFSF13B protein, human